Late Hony. Surg. Cmde. Dr. Shantilal C. Sheth Oration Presentation during PEDICON 2006 Delhi, January 6th, 2006. Progress in the management of thalassemia

Indian Pediatrics

Volumn 43, Issue 6, 2006, Pages 503-506

  Lokeshwar, M R ^a,b,c  

^a P D HINDUJA NATIONAL HOSPITAL   (India)

^b LILAVATI HOSPITAL AND RESEARCH CENTRE   (India)

^c Imperial Mahal   (India)

Author keywords

[No Author keywords available]

Indexed keywords

ACETOACETIC ACID; DEFERASIROX; DEFERIPRONE; DEFEROXAMINE; HEPATITIS B VACCINE; IRON CHELATING AGENT; PYRIDOXAL ISONICOTINOYLHYDRAZONE;

BLOOD TRANSFUSION; CYTOMEGALOVIRUS; ERYTHROCYTE CONCENTRATE; GENE THERAPY; HEALTH CARE COST; HEPATITIS B; HEPATITIS C; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IRON OVERLOAD; MALARIA; NONHUMAN; POSTTRANSFUSION HEPATITIS; PRACTICE GUIDELINE; PRENATAL DIAGNOSIS; REVIEW; STEM CELL TRANSPLANTATION; THALASSEMIA; UNSPECIFIED SIDE EFFECT; VIRUS INFECTION; YERSINIOSIS;

BLOOD TRANSFUSION; CHILD; GENE THERAPY; HUMANS; INDIA; IRON CHELATING AGENTS; STEM CELL TRANSPLANTATION; THALASSEMIA;

EID: 33745883771     PISSN: 00196061     EISSN: 00196061     Source Type: Journal    
DOI: None     Document Type: Review

References (17)

1. Amarapurkar DN, Kumar A, Vaidya S, Murti P, Bichile SK, Kalro RH, et al. Frequency of Hepatitis B, C and D and HIV infection in multitransfused Thalassemics. Indian J Gastroenterol 1992 ;11: 80-81.
2. Chakravarti A, Verma V, Kumaria R, Dubey AP. Anti-HCV seropositivity among multiple transfused patients with beta thalassaemia. J Indian Med Assoc. 2005;103: 64-66.
3. Choudary N, Saraswat S, Naveed M. Serological monitoring of Thalassemia major patients for transfusion associated viral infections. Indian J Meds Res 1998;107: 263-268.
4. Olivieri NF, Brittenham GM, Matsui D, Berkovitch M, Blendis LM, Cameron RG, et al. Iron-chelation therapy with oral deferipronein patients with thalassemia major. N Engl J Med. 1995; 332: 918-922.
5. Kontoghiorghes GJ, Agarwal MB, Tondury P, Marx JJ. Deferiprone or fatal iron toxic effects? Lancet. 2001; 357: 882-883
6. Kusher JP, Porter J, Olivieri NF. Secondary Iron Overload. Hematology. 2001; 47 - 61.
7. Addis A, Loebstein R, Koren G, Einarson TR. Meta-analytic review of the clinical effectiveness of deferiprone (L1). Eur J Clin Pharmacol.1999; 55: 1-6.
8. Hershko G, Hoffbrand AV. Iron chelation therapy. Rev Clin Exp Haematol. 2001; 4: 337-361.
9. Giardina PJ, Grady RW. Chelation Therapy in β-Thalassemia: An Optimistic Update. Semin Hematol. 2001; 38 (4): 360-366.
10. Grady RW, Giardina PJ. Oral iron chelators: a potential role of HBED in combination therapy (Abstract). Blood 1999; 94: 3293a.
11. Grady RW, Salble AD, Hilagartner MW, Giardina PJ. Result from a Phase I clinical trial of HBED. Adv Exper Med Biol 1994; 36: 351-359.
12. Richardsonn DR, Ponka P. Pyridoxal isonicotinoyl hydrazone and its analogs: potential orally effective iron chelating agents for the treatment of iron overloads disease. J Lab Clin Med 1998;131: 306-314.
13. Ponka P, Borova J, Neuwirth J, Fuchs O, Necas E. A study for Intracellular iron metabolism using pyridoxal isonicotinoyl hydrazone and other synthetic chelating agents. Biochim Biophys Acta 1979;586:278-297.
14. Cappellini MD. Iron-Chelating, with the new oral agent ICL670 (Exjade). Best practise and research. Clinical Haematology 2005;18: 289-298.
15. Galanello R, Piga A, Alberti D, Rouan MC, Bigler H, Sechaud R. Safety, tolerability, and pharmacokinetics of ICL670, a new orally active iron-chelating agent in patients with transfusion-dependent iron overload due to beta-thalassemia. J Clin Pharmacol. 2003; 43: 565-572.
16. Agarwal MB. ICL 670: a new oral chelator: a major breakthrough in treatment of Thalassemia. Indian J Hematol Blood Transfusion 2003; 31:26-28.
17. Mourad FH, Hoffbrand AV, Sheikh-Taha M, Koussa S, Khoriaty AI, Taher A. Comparison between desferrioxamine and combined therapy with desferrioxamine and deferiprone in iron overloaded thalassaemia patients. Br J Hematol. 2003; 121:187-189.